|Description||(±)-Clopidogrel hydrochloride is the hydrochloride salt of clopidogrel, which is a high affinity, selective and irreversible antagonist of the platelet purinergic P2Y12 receptor with IC50 value of 100 nM. It is used as a potent antithrombotic agent and requires bioactivation. It inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug. It enables its anti-aggregating activity via biotransformation to its active metabolite via CYP2C19 in the liver.|
|Purity||≥99% by HPLC|
|Synonyms||Plavix; α-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid, methyl ester, monohydrochloride; Methyl 2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl)-2-(2-chlorophenyl)acetate hydrochloride|
Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.
Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors. The blockade of P2Y12 receptor act...
MRS 2179 tetrasodium salt
MRS 2179 tetrasodium salt is a competitive antagonist at P2Y1 receptors (KB = 100 nM), which is selective over P2X1 (IC50 = 1.15 μM), P2X3 (IC50 = 12.9 μM), P2X...
Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.
MRS 2211 is a competitive P2Y13 receptor antagonist (pIC50 = 5.97), with > 20-fold selectivity over P2Y1 and P2Y12 receptors. It is known that MRS 2211 inhibits...
MRS 2279 is the first broadly applicable, selective and high affinity competitive antagonist radioligand for a P2Y receptor (Ki = 2.5 nM; IC50 = 51.6 nM).
SAR 216471 hydrochloride
SAR 216471 hydrochloride is a potent and reversible P2Y12 antagonist (IC50 = 17 nM), displaying antiplatelet and antithrombotic activity in vivo.
MRS 2957 triethylammonium salt
MRS 2957 triethylammonium salt 7 is a selective P2Y6 receptor agonists (EC50 = 12 nM) for the treatment of muscle wasting and neurodegeneration. It exhibits 14-...